Ginkgo Bioworks Holdings Inc at JPMorgan Healthcare Conference Transcript
Hi, everyone. Thanks for coming. I'm from the life science tools and diagnostics team at JPMorgan. Welcome to the 2024 JPMorgan Healthcare Conference. So we're about to do about 20 minutes of questions and 20 minutes of Q&A.
And with that, I'd like to welcome CEO, Jason Kelly from Ginkgo Bioworks.
All right. Thank you. Sure, why not? Yes. Clap it in. Appreciate that. So I'm Jason Kelly, I'm the Co-Founder and CEO at Ginkgo Bioworks. I'm super excited to talk to you today about the progress Ginkgo has made in 2023, especially the work we've been doing in biopharma. I really consider this to be kind of a breakout year for us in that market. So excited to talk about that. And also I want to spend a little time on why I see Ginkgo as sort of general purpose infrastructure for biopharma R&D in the second half of the talk.
Before I get to that, I will be making forward-looking statements for a public company. When you have a chance, feel free to read
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |